BR112022013236A2 - Anticorpos anti-cd73 e usos dos mesmos - Google Patents

Anticorpos anti-cd73 e usos dos mesmos

Info

Publication number
BR112022013236A2
BR112022013236A2 BR112022013236A BR112022013236A BR112022013236A2 BR 112022013236 A2 BR112022013236 A2 BR 112022013236A2 BR 112022013236 A BR112022013236 A BR 112022013236A BR 112022013236 A BR112022013236 A BR 112022013236A BR 112022013236 A2 BR112022013236 A2 BR 112022013236A2
Authority
BR
Brazil
Prior art keywords
antibodies
disclosed
vectors
cells
nucleic acids
Prior art date
Application number
BR112022013236A
Other languages
English (en)
Inventor
G NASTRI Horacio
M Stewart Shaun
Carlos Almagro Juan
Zhou Jing
A Buonpane Rebecca
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of BR112022013236A2 publication Critical patent/BR112022013236A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPOS ANTI-CD73 E USOS DOS MESMOS. A presente invenção refere-se a anticorpos anti-CD73 que são divulgados. Também são divulgados ácidos nucleicos, vetores, células e composições farmacêuticas relacionados. Métodos para tratar câncer com os anticorpos anti-CD73 também são divulgados.
BR112022013236A 2020-01-03 2020-12-30 Anticorpos anti-cd73 e usos dos mesmos BR112022013236A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062956847P 2020-01-03 2020-01-03
PCT/US2020/067533 WO2021138467A1 (en) 2020-01-03 2020-12-30 Anti-cd73 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112022013236A2 true BR112022013236A2 (pt) 2022-09-06

Family

ID=74347717

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013236A BR112022013236A2 (pt) 2020-01-03 2020-12-30 Anticorpos anti-cd73 e usos dos mesmos

Country Status (17)

Country Link
EP (1) EP4084825A1 (pt)
JP (1) JP2023509448A (pt)
KR (1) KR20220121850A (pt)
CN (1) CN115135341A (pt)
AR (1) AR120936A1 (pt)
AU (1) AU2020417804A1 (pt)
BR (1) BR112022013236A2 (pt)
CA (1) CA3166533A1 (pt)
CL (1) CL2022001769A1 (pt)
CO (1) CO2022009248A2 (pt)
CR (1) CR20220317A (pt)
EC (1) ECSP22051701A (pt)
IL (1) IL294436A (pt)
MX (1) MX2022007575A (pt)
PE (1) PE20221409A1 (pt)
TW (1) TW202128768A (pt)
WO (1) WO2021138467A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
IL300821A (en) 2018-07-05 2023-04-01 Incyte Corp Fused pyrazine derivatives as A2A/A2B inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
CN117500503A (zh) * 2020-12-29 2024-02-02 因赛特公司 包含a2a/a2b抑制剂、pd-1/pd-l1抑制剂和抗cd73抗体的组合疗法
CN113025567A (zh) * 2021-03-31 2021-06-25 中国人民解放军陆军特色医学中心 一种椎间盘单细胞的分离方法
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
NZ544486A (en) 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
EP2502935B1 (en) 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
RS62003B1 (sr) * 2014-11-10 2021-07-30 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (en) * 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
PE20170782A1 (es) * 2014-11-21 2017-07-04 Bristol Myers Squibb Co Anticuerpos frente a cd73 y usos de los mismos
KR20180118725A (ko) * 2016-03-04 2018-10-31 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
US10793636B2 (en) * 2016-07-11 2020-10-06 Corvus Pharmaceuticals, Inc. Anti-CD73 antibodies
ES2908662T3 (es) * 2017-01-24 2022-05-03 I Mab Biopharma Us Ltd Anticuerpos anti-CD73 y usos de los mismos
WO2019173692A2 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
BR112020016049A2 (pt) * 2018-03-09 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anti-cd73 e seus usos
WO2019232244A2 (en) * 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof

Also Published As

Publication number Publication date
PE20221409A1 (es) 2022-09-20
JP2023509448A (ja) 2023-03-08
KR20220121850A (ko) 2022-09-01
CN115135341A (zh) 2022-09-30
US20210230293A1 (en) 2021-07-29
TW202128768A (zh) 2021-08-01
EP4084825A1 (en) 2022-11-09
CR20220317A (es) 2022-09-02
ECSP22051701A (es) 2022-08-31
CL2022001769A1 (es) 2023-01-20
IL294436A (en) 2022-09-01
MX2022007575A (es) 2022-09-23
AR120936A1 (es) 2022-03-30
WO2021138467A1 (en) 2021-07-08
AU2020417804A1 (en) 2022-07-21
CO2022009248A2 (es) 2022-08-19
CA3166533A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
BR112017009835A2 (pt) moléculas de ácido nucleico artificiais
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018006547A2 (pt) anticorpos de pd-1 e usos dos mesmos
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
BR112017014328A2 (pt) anticorpos compreendendo um domínio de ligação de antígeno dependente de concentração de íon, variantes de região fc, anticorpos de ligação à il-8, métodos de produção dos mesmos e para prolongamento ou redução da meia-vida de um anticorpo em plasma, composição farmacêutica, ácido nucleico, vetor, célula hospedeira
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
AR115389A1 (es) Anticuerpo antagonista de cd73
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
BR112021020867A2 (pt) Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
BR112015022780A2 (pt) reticuladores de produto químico
BR112021024080A2 (pt) Construtos de rnai para inibir a expressão de scap e métodos de uso dos mesmos
BR112022020410A2 (pt) Anticorpos anti-phf-tau e usos dos mesmos
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos